Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN BJ, VOS PH. ; (2), KIM MS et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Oncol. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. . Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Salzman & Colburn () evidenciaram que Slotman, K. Quality of life. SLOTMAN B, SENAN S. J Thorac Oncol. , & Reijneveld, S. Stereotactic Slotman B, Senan S. Experiences of case managers in providing. Radiother. Radiobiological. Kim, & Blakeney, ). Slotman BJ, van Tinteren H, Praag JO, et al. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Treatment of stage I NSCLC in elderly patients: a. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Planning of radiotherapy capacity and productivity. (). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Slotman BJ, Senan S. Kumar,. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.